ORAMED PHARMACEUTICALS INC. Available-for-sale Securities, Gross Unrealized Gain
ORAMED PHARMACEUTICALS INC. (ORMP) reported Available-for-sale Securities, Gross Unrealized Gain of -$1.00 thousand for the 9-month period ending 2017-05-31, per its 10-Q filed 2017-07-06.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedGains · last filed 2017-07-06
- ORAMED PHARMACEUTICALS INC. available-for-sale securities, gross unrealized gain for the quarter ending 2017-05-31 was -$2.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain 3 month | Available-for-sale Securities, Gross Unrealized Gain 6 month | Available-for-sale Securities, Gross Unrealized Gain 9 month | Available-for-sale Securities, Gross Unrealized Gain 12 month |
|---|---|---|---|---|
| 2017-05-31 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-07-06 | -$1.00K 10-Q · filed 2017-07-06 | ||
| 2017-02-28 | $1.00K 10-Q · filed 2017-04-05 | |||
| 2016-08-31 | $1.00K 10-Q · filed 2017-07-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |